PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications
PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, has completed a 7.3 million euro capital increase. The company will focus on intensifying international growth, supported by initial, promising sales.
Micro-Chip chromatography company PharmaFluidics closed a financing round of 7.3 million euro from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round. The VUB spin-off is a disruptive player in the field of micro-Chip Chromatography. Their unique technology – the µPACᵀᴹ column series – offers unprecedented robustness and reproducibility as well as state-of-the-art sensitivity and resolution performance. The first clients – academic labs in bio-analysis, bio-pharmaceuticals and diagnostics companies – have confirmed these outstanding characteristics of the µPACᵀᴹ technology. The new funds will be used to further develop the Pillar Array technology platform, to expand the µPACᵀᴹ product range, and to scale up production and global sales. “This funding will significantly boost our capacity to support our growth,” said PharmaFluidics’ Managing Director Johan Devenyns. Intensified commercialization The company started shipping µPACᵀᴹ columns in September 2017 and has since served proteomics laboratories, medical centers and pharmaceutical companies on three continents: Europe, the USA and Asia. Its pioneering product is very well received and has convinced pioneer users and key opinion leaders in proteomics to use micro-Chip based chromatography. The unique performance of the µPACᵀᴹ columns brings groundbreaking applications within reach. For example, the robustness and reproducibility allow proteomics data from different labs to be pooled, making reliable big data analysis possible. The miniaturization and sensitivity open the door to point-of-care nano-LC-MS, or ultimately single-cell analyses. This market validation as well as the additional potential in new markets have convinced serial life sciences investors RMM SA and Heran BVBA to participate in the current funding round. About PharmaFluidics The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence, pioneer users and global Mass Spectrometry instrument providers to develop an increasing range of applications. The µPACᵀᴹ started shipping commercially in September 2017. More info: www.pharmafluidics.com About FPIM-SFPI More info: www.sfpi-fpim.be About Mrs. Annie Vereecken Mrs. Annie Vereecken started as an entrepreneur in gynecological endocrinology and pathology, from where she built a business in clinical labs, which was ultimately sold to Sonic Healthcare in 2010. She has actively re-invested in life sciences companies. including a.o. Argenx, Biocartis, MyCartis, Cartagenia (later acquired by Agilent), Ugentec. About Mr. Rudi Mariën About Qbic More info: www.qbic.be About PMV More info: www.pmv.eu About Theodorus Fund More info: www.theodorus.be About Innovation Fund Created in February 2015, Innovation Fund invests in innovative startups and companies active in the field of chemistry and life sciences. The fund has a capital of EUR 28 million, financed for more than 70% by major companies of the sector such as Total, Solvay, BASF, Sioen, Recticel, Ravago, Arkema, Sioen, Recticel, Soudal, Carmeuse, Hutchinson, Christeyns…, bringing unique industrial support value to the invested projects. The remaining 30% are held by national and regional investment funds, KULeuven, Ghent University, University of Antwerp and ING. Today, the Innovation Fund has already invested in 14 companies. More info: www.innovationfund.eu About Volksvermogen More info: www.volksvermogen.be |